SCHEMBL26837233

SCHEMBL26837233

CC1Cc2c(oc3ccc(O)cc23)C2CCCN1C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ PIK3CA P42336 2/20 0.39
▸ PIK3CG P48736 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CHRNB2 P17787 1/20 0.37
▸ CHRNA4 P43681 1/20 0.37
▸ PRKD1 Q15139 3/20 0.35
▸ TP53 P04637 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ CDK5 Q00535 1/20 0.34
▸ CDK5R1 Q15078 1/20 0.34
▸ PRKD2 Q9BZL6 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.33
▸ NFKB1 P19838 1/20 0.32
▸ PRCP P42785 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26837240 0.77 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19PIK3CAPIK3CG
SCHEMBL26837252 0.75 ESR1 (0.46) —
SCHEMBL26927708 0.71 CYP1A2 (0.36) CYP1A2CYP3A4CYP2C19PIK3CAPIK3CG
SCHEMBL26838578 0.71 CYP3A4 (0.52) CYP1A2CYP3A4CYP2C19ALDH1A1LMNA
SCHEMBL31622901 0.71 CYP1A2 (0.37) CYP1A2CYP3A4CYP2C19PIK3CAPIK3CG
SCHEMBL26675964 0.68 CYP3A4 (0.55) CYP1A2CYP3A4CYP2C19ALDH1A1LMNA
SCHEMBL29736086 0.68 CYP3A4 (0.55) CYP1A2CYP3A4CYP2C19ALDH1A1LMNA
SCHEMBL17793530 0.66 SLC6A4 (0.46) CYP1A2CYP3A4CYP2C19PIK3CAPIK3CG
SCHEMBL17793566 0.66 SLC6A4 (0.46) CYP1A2CYP3A4CYP2C19PIK3CAPIK3CG
SCHEMBL17793531 0.66 SLC6A4 (0.46) CYP1A2CYP3A4CYP2C19PIK3CAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382919-A1 OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-11-30 — — US disclosed
US-20230382919-A1 OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382919-A1 OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS GRIA4, GRIA3, GRIN3A CYP1A2 400/4885CYP3A4 238/4885CYP2C19 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback